HC Wainwright & Co. Maintains Buy on Biohaven, Raises Price Target to $63
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has maintained a Buy rating on Biohaven (NYSE:BHVN) and increased the price target from $50 to $63.

March 04, 2024 | 11:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biohaven's Buy rating is maintained by HC Wainwright & Co., with the price target raised from $50 to $63.
The increase in price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong bullish outlook on the stock, suggesting potential upside. This is based on the firm's analysis and confidence in Biohaven's future performance, which could positively influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100